Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Extendin-4
Drug ID BADD_D00863
Description Exenatide is a glucagon-like peptide-1 (GLP-1) analog[Label]. It functions to activate the GLP-1 receptor and increases insulin secretion, decrease glucagon secretion, and slow gastric emptying to improve glycemic control[Label]. Exenatide was given FDA approval on April 28, 2005[L6106].
Indications and Usage Indicated as adjunctive therapy to improve glycemic control in patients with Type 2 diabetes mellitus who are taking metformin, a sulfonylurea, or a combination of both, but have not achieved adequate glycemic control.
Marketing Status Prescription
ATC Code A10BJ01
DrugBank ID DB01276
KEGG ID D04121
MeSH ID D000077270
PubChem ID 16157882
TTD Drug ID D00YVF
NDC Product Code 0406-7310; 0310-6524; 62756-040; 0310-6512; 52416-125; 0310-6530; 41524-0003; 52416-105; 69766-078; 0310-6540
Synonyms Exenatide | Bydureon | ITCA 650 | AC 2993 LAR | Exendin-4 | Ex4 Peptide | Peptide, Ex4 | Exendin 4 | Byetta | AC 2993
Chemical Information
Molecular Formula C184H282N50O60S
CAS Registry Number 141758-74-9
SMILES CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN )C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC( C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC( =O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C( CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO )NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC (=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CN=CN9)N
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscle spasms15.05.03.004--
Musculoskeletal pain15.03.04.007--
Nasopharyngitis22.07.03.002; 11.01.13.002--Not Available
Nausea07.01.07.001--
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Pain in extremity15.03.04.010--
Pancreatitis acute07.18.01.002--Not Available
Pancreatitis necrotising07.18.01.004--Not Available
Pruritus23.03.12.001--
Rash papular23.03.13.017--Not Available
Renal failure20.01.03.005--Not Available
Seizure17.12.03.001--
Sinusitis22.07.03.007; 11.01.13.005--
Skin disorder23.03.03.007--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Tachycardia02.03.02.007--Not Available
Toothache07.09.06.001--
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urethral disorder20.07.01.002--Not Available
Urinary tract disorder20.08.01.001--Not Available
Urinary tract infection20.08.02.001; 11.01.14.004--
Urticaria23.04.02.001; 10.01.06.001--
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Viral diarrhoea11.05.04.012; 07.19.02.008--Not Available
Pruritus generalised23.03.12.003--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Nodule08.03.05.002--Not Available
Neuroglycopenia17.02.05.046; 14.06.03.009; 05.06.03.009--Not Available
The 3th Page    First    Pre   3 4    Next   Last    Total 4 Pages